A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Ajulemic acid (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Corbus Pharmaceuticals
- 08 Aug 2018 According to a Corbus Pharmaceuticals media release, the company expects to report topline results for this study in the first half of 2020.
- 08 Aug 2018 According to a Corbus Pharmaceuticals media release, this study was designed with input from the Therapeutic Development Network of the Cystic Fibrosis Foundation and the European Cystic Fibrosis Society Clinical Trials Network. FDA provided guidance on the overall study design.
- 14 Jun 2018 According to a Corbus Pharmaceuticals media release, in support of this study, Corbus received a Development Award for up to $25 million from the Cystic Fibrosis Foundation.